Business Wire

Swissmedic Approves Carbetocin Ferring for the Prevention of Postpartum Haemorrhagein All Births

Share

Ferring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section.5

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005290/en/

Nigeria: Anita suffered from postpartum haemorrhage after the birth of her first child, and needed a blood transfusion to save her life. (Photo: Business Wire)

Nigeria: Anita suffered from postpartum haemorrhage after the birth of her first child, and needed a blood transfusion to save her life. (Photo: Business Wire)

Every year, 14 million women experience excessive bleeding after birth, also known as postpartum haemorrhage (PPH),2 which leads to approximately 70,000 deaths per year.1 Although most deaths are preventable, PPH is the leading direct cause of maternal death worldwide,1 99% of which occur in low- and lower-middle income countries.2

Carbetocin Ferring is the first medicine approved under the new Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products (MAGHP). The MAGHP procedure builds on the existing Swissmedic procedure for Marketing Authorisation and makes it accessible to representatives of regulatory authorities in low- and middle-income countries. The procedure’s objective is to make essential medicines, like Carbetocin Ferring, available faster for patients in low- and middle-income countries.4

“As the COVID-19 pandemic impacts healthcare systems, communities and families all over the world, protecting maternal health has never been so critical. This milestone approval marks the first step towards ensuring that this innovative medicine reaches the women who need it – and reducing the thousands of preventable deaths from PPH every year, said Per Falk, President and Chief Science Officer at Ferring Pharmaceuticals. It is thanks to the collaboration with the World Health Organization and MSD for Mothers that we can mark this milestone and work towards development goals in global health.”

This landmark approval in Switzerland paves the way as Ferring now seeks registrations for Carbetocin Ferring for the prevention of PPH following all births, in low- and lower-middle income countries, where the burden of maternal mortality is greatest.2 Ferring is initially working with governments and partners in India, Kenya and Nigeria to secure the approval and introduction of Carbetocin Ferring, so that patients who need it can access it as soon as possible.

“This regulatory milestone is testament to the potential that public-private partnerships hold to address public health challenges, said Dr Julie L. Gerberding, Chief Patient Officer at MSD. Our ultimate goal through MSD for Mothers is to help create a world where no woman has to die while giving life. Today’s announcement brings us one step closer to realising this vision by improving the response to prevent PPH.”

Carbetocin Ferring ampoules will be made available by Ferring at an affordable and sustainable price* to publicly controlled or publicly funded healthcare facilities and healthcare facilities operating on a not-for-profit basis, including through social marketing, in low- and lower-middle income countries. Ferring will supply Carbetocin Ferring from state-of-the-art manufacturing sites that have passed Good Practice Manufacturing inspections by stringent regulatory authorities.7

“The loss of any woman during childbirth is a tragedy. Yet so many of the deaths caused by postpartum haemorrhage can be prevented, said Dr. Yeshita V Pujar, Consultant gynaecologist-obstetrician, KLES Prabhakar Kore Hospital & Medical Research Centre, Karnataka, India. This heat-stable formulation of carbetocin will play an important role in PPH prevention in countries which carry the greatest burden of maternal mortality, especially low- and lower-middle income countries. Many of these are in hotter parts of the world where cold-chain storage remains difficult to achieve and maintain. A heat-stable alternative for the prevention of PPH will be critical in saving maternal lives in settings where other effective uterotonics are unavailable or their quality cannot be guaranteed.”

Heat-stable carbetocin is included on the World Health Organization (WHO) Model List of Essential Medicines (EML),8 and in the WHO recommendations on uterotonics for the prevention of postpartum haemorrhage. The EML identifies medicines essential for addressing the most important public health needs globally.7 The guidelines recommend heat-stable carbetocin for the prevention of PPH in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics.**6

About the CHAMPION trial9
CHAMPION (Carbetocin Haemorrhage Prevention), the largest clinical trial in the prevention of PPH,*** was a double-blind, randomised, non-inferiority trial designed to compare the effectiveness and safety of investigational heat-stable carbetocin to oxytocin in the prevention of PPH after vaginal birth. The trial was funded by MSD for Mothers.**** Heat-stable carbetocin is a long-acting uterotonic developed by Ferring Pharmaceuticals.

* This price is a subsidised price of $0.31 +/- 10% per ampoule of 100 µg Carbetocin Ferring, Ex Works. This is comparable to the current United Nations Population Fund price for oxytocin of $0.32 per unit (10 I.U.).10
** The availability of Carbetocin Ferring is subject to regulatory review and approval in relevant countries.
*** Accurate as of trial closure in 2018
**** MSD for Mothers is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build healthy families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

References
1 Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2(6):e323-e333. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed: May 2020
2 WHO. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed: May 2020
3 Swissmedic. First MAGHP approval in Switzerland. Available at: https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/informationen/first-maghp-approval-inswitzerland.html Last accessed: May 2020
4 Swissmedic. Swissmedic procedure for scientific advice and Marketing Authorisation for Global Health Products (MAGHP). Available at: https://www.swissmedic.ch/swissmedic/en/home/about-us/development-cooperation/marketing-authorisation-for-global-health-products.html Last accessed: May 2020
5 World Bank. World Bank Country and Lending Groups. Published 2019. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups Last accessed: May 2020
6 WHO. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Available at: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1 Last accessed: May 2020
7 Data on file
8 WHO Model List of Essential Medicines. Available at: https://apps.who.int/iris/handle/10665/325771 Last accessed: May 2020
9 Widmer M, et al. Heat stable carbetocin vs oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine 2018;379:743-752
10 UNFPA Procurement Services. Oxytocin 10 I.U./ml injection in 1ml ampoule. www.unfpaprocurement.org/products?id=OXYTOCIN_10IU/ML Last accessed: May 2020

Contact information

For more information, please contact

Bhavin Vaid
Head of Corporate Communications
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Lindsey Rodger
Senior Manager, Corporate Communications
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom